IMRN

Stock ticker: NASDAQ

PRICE

CHANGE

CAPITALIZATION

Immuron (IMRN) Ownership - Who owns Immuron?

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis... Show more

Industry: #Biotechnology

Get AI intraday signals

#MovingAverage #Momentum #MACD #Pattern #RSI #Stochastic #Aroon #Bollinger

Profile

Industry

Biotechnology

Address

Chapman Street

Phone

+61 398245254

Employees

Web

https://www.immuron.com.au

Details

Group

Domestic Stock Funds

Fundamentals

IMRN

Capitalization

9.48M

P/E Ratio

N/A

Risk (Beta)

1.32

Dividend Yield

N/A

Total Cash

7.74M

Total Cash/Share

1.35

Total Debt

N/A

Total Debt/Equity

N/A

Projected Growth (PEG Ratio)

N/A

Revenue/Share (as % of the share price)

0.73%

Revenue

6.54M

ROE

N/A

Book Value

10.3M

P/B Ratio

1.56

Cash Flow

N/A

Earnings

-1.29

Average Daily Volume YTD

N/A

Common Shares Outstanding - Security Level

88.6M

Current Ratio

6.80

Current Revenue Per Employee

N/A

Dividends Per Share - Security

N/A

EBITDA

-7.35M

Float

N/A

Float - Current

N/A

Gross Income Margin

N/A

Revenue To Assets

-45.88

Shares Held By Institutions

10.5K

Shares Outstanding - Current

5.73M

Total Liabilities

1.83M

Total Volume MTD

N/A

Value

N/A

Gain YTD

5.453

View a ticker or compare two or three

Compare

Ad is loading...

A.I.Advisor

published price charts

A.I. Advisor

published General Information

General Information

a biopharmaceutical company

Industry Biotechnology